Pentalogy of Cantrell Clinical Trial
Official title:
Mutations in Genes Associated With Pentalogy of Cantrell
| Verified date | October 2020 |
| Source | National Institutes of Health Clinical Center (CC) |
| Contact | n/a |
| Is FDA regulated | No |
| Health authority | |
| Study type | Observational |
This study will collect blood, urine, and other tissue samples from patients with Pentalogy
of Cantrell (POC) and other inherited diseases that may involve mutations in non-muscle
myosin II-B heavy chain (MYH10). We will also collect samples from the relatives of affected
individuals. POC is a very rare disorder in which patients have a combination of severe
defects of the middle of the chest including the sternum (breastbone), diaphragm, heart, and
abdominal wall. The defect are apparent before birth or at birth.
Participants may undergo a medical evaluation that could include a medical history routine
blood tests, urine collection, chest x-ray, and electrocardiogram. In addition, blood, urine,
saliva, buccal swab or tissue samples may be collected for protein and gene studies. The
blood is drawn through a very small needle placed in an arm vein. Children may choose to have
a buccal (cheek) sample taken instead of blood draw. Buccal samples can be collected by a
cheek swab, in which a soft brush is rubbed on the inside lining of the mouth, or by having
the child hold a tablespoon of mouthwash in his or her mouth for a full minute and then spit
the mouthwash into a container. In addition, tissue samples may be collected from patients if
they undergoing any surgical procedures that may be required as part of their general medical
care.
Some of the cells obtained from patients or their relatives may be used to establish cell
lines (a living tissue sample) that can be grown in the laboratory and used for experiments.
...
| Status | Completed |
| Enrollment | 59 |
| Est. completion date | September 6, 2019 |
| Est. primary completion date | September 6, 2019 |
| Accepts healthy volunteers | No |
| Gender | All |
| Age group | N/A to 100 Years |
| Eligibility |
- INCLUSION CRITERIA: i. Index Cases 1. Those patients who have a diagnosis of POC or other related syndromes (as defined under Study Design) confirmed by telephone discussion between the investigators and the patient s physician. 2. Outside Institutions- All ages will be included 3. At the Clinical Center - Those subjects that are greater than or equal to 2 years of age and older. ii. Relatives of Index Cases 1. We may obtain samples from family members and/or relatives of those individuals who have a diagnosis of POC or other related syndrome confirmed by telephone discussion between the investigators and the referring physician with knowledge of the index case. 2. Outside Institutions - All ages will be included. At the Clinical Center - Those subjects that are greater than or equal to 2 years of age and older iii. Fetal tissue: 1. We may obtain samples from patients with a fetal diagnosis of POC or other related syndrome with diagnosis confirmed by telephone discussion between the investigators and the referring physician. 2. Research use of the fetal tissue in accordance to NIH Division of Intramural Research (DIR) Program fetal tissue policy guidelines: 1. No profits will be involved; 2. NIH researchers will have no involvement in the termination of pregnancy, and 3. The tissue must be obtained in accordance with Federal, state, and local law including those that govern basic research using human fetal tissue and research involving the transplantation of fetal tissue. EXCLUSION CRITERIA: Subjects seen at the Clinical Center - Those subjects that are less than or equal to 2 years of age and older. |
| Country | Name | City | State |
|---|---|---|---|
| United States | National Institutes of Health Clinical Center, 9000 Rockville Pike | Bethesda | Maryland |
| United States | Baylor College of Medicine | Houston | Texas |
| Lead Sponsor | Collaborator |
|---|---|
| National Heart, Lung, and Blood Institute (NHLBI) |
United States,
Ma X, Adelstein RS. A point mutation in Myh10 causes major defects in heart development and body wall closure. Circ Cardiovasc Genet. 2014 Jun;7(3):257-65. doi: 10.1161/CIRCGENETICS.113.000455. Epub 2014 May 13. Erratum in: Circ Cardiovasc Genet. 2014 Aug;7(4):570. — View Citation
Ma X, Adelstein RS. In vivo studies on nonmuscle myosin II expression and function in heart development. Front Biosci (Landmark Ed). 2012 Jan 1;17:545-55. Review. — View Citation
Ma X, Adelstein RS. The role of vertebrate nonmuscle Myosin II in development and human disease. Bioarchitecture. 2014;4(3):88-102. doi: 10.4161/bioa.29766. Epub 2014 Aug 6. Review. — View Citation
| Type | Measure | Description | Time frame | Safety issue |
|---|---|---|---|---|
| Primary | Identify the gene(s) mutation (s) that causes Pentalogy of Cantrell | Identification of novel genes related to Pentalogy of Cantrell | ongoing | |
| Secondary | Since mutations in NM IIB may not be the sole cause of POC, we also intend to identify any other gene(s) mutation(s) that might be thecause of POC. | Identifying any other gene(s) mutation(s) that might be the cause of POC. | Ongoing | |
| Secondary | We may wish to procure tissues from patients with nonmuscle myosin IIA and IIC mutations in order to study the mechanism underlyingthese abnormalities. | Studying the mechanism underlying these abnormalities in procuredtissues from patients with nonmuscle myosin IIA and IIC mutations. | Ongoing |
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Withdrawn |
NCT00477932 -
Genes Mutation Pentalogy of Cantrell
|
N/A | |
| Completed |
NCT02430376 -
dbGaP Protocol: Genetic Variants Associated With Pentalogy of Cantrell
|